Skip to main content
. 2015 Mar 20;1(2):e1400026. doi: 10.1126/sciadv.1400026

Fig. 2. Age-related variation in risks of T. parva infection, clinical illness, and death from ECF.

Fig. 2

(A) Empirical estimates of (i) hazard of seroconversion to T. parva (18), with censoring of non–T. parva–related deaths and adjusted for a 14-day delay between infection and a detectable antibody response; (ii) case fatality rate (probability of death conditional on infection, CF); (iii) net clinical rate (probability of death or ECF-like illness conditional on infection, CL). In contrast to hazard, CF and CL both decrease with age (Poisson regression: F1,8 = 10.4, P = 0.012 and F1,8 = 57.7, P < 0.001, respectively). (B) Model-predicted estimates for hazard and corresponding predictions for CF and CL with age. Model equations are given in Materials and Methods; parameter estimates are as in Table 3.